In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

The Food and Drug Administration (FDA) has approved Enhertu ® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

After hours: February 12 at 6:37:58 PM EST Loading Chart for MGPI ...

The ERROR_PWD_TOO_LONG with error code 657 (0x291) and description The password provided is too long to meet the policy of your user account. Please choose a shorter ...

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection. Kindly note the image has been posted only for representational purposes. Photograph: Kind courtesy Thirdman/Pexels.com With ...

A unified persons with disability (PWD) identification (ID) system will be implemented by the end of the year, the Department of Social Welfare and Development (DSWD) said Sunday. “By the end of this ...

With the rising incidence of cancer in India, AstraZeneca India’s breast cancer medicine trastuzumab deruxtecan (sold under the brand name Enhertu) emerged as the highest-selling new drug brand ...

9. “By the end of this year, mayroon na po tayong unified [PWD] ID (we will have a unified ID),” Assistant Secretary Irene Dumlao, the spokesperson of the DSWD, said in a radio interview. The ...

Promises that the products’ actives – ingredients that target specific concerns – will be the magic bullet to solve our skin woes can be confusing and overwhelming. And who has the energy ...